| scholarly article | Q13442814 |
| P50 | author | Courtney G Sansam | Q57992464 |
| Pablo Tamayo | Q59551108 | ||
| Charles W Roberts | Q60678094 | ||
| P2093 | author name string | Jill P Mesirov | |
| Justin Klekota | |||
| Tewis Bouwmeester | |||
| Peter J Park | |||
| Sarah J Luchansky | |||
| Joshua Murtie | |||
| William R Sellers | |||
| Heinz Ruffner | |||
| Yoon-Jae Cho | |||
| Scott L Pomeroy | |||
| Silvia Buonamici | |||
| Markus Warmuth | |||
| Boris Wilson | |||
| Dongshu Chen | |||
| Marion Dorsch | |||
| Zainab Jagani | |||
| E Lorena Mora-Blanco | |||
| Kathy Hsiao | |||
| Elizabeth S McKenna | |||
| Joseph F Kelleher | |||
| Michael Tolstorukov | |||
| Phuong T L Nguyen | |||
| P2860 | cites work | A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway | Q21735927 |
| Mammalian suppressor-of-fused modulates nuclear-cytoplasmic shuttling of Gli-1 | Q22010791 | ||
| SWI/SNF complex interacts with tumor suppressor p53 and is necessary for the activation of p53-mediated transcription | Q24294282 | ||
| Constitutional mutations of the hSNF5/INI1 gene predispose to a variety of cancers | Q24534231 | ||
| Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles | Q24536351 | ||
| Small-molecule modulators of Hedgehog signaling: identification and characterization of Smoothened agonists and antagonists | Q24794838 | ||
| Exploration, normalization, and summaries of high density oligonucleotide array probe level data | Q27861098 | ||
| Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma | Q28237604 | ||
| Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer | Q28277002 | ||
| The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas | Q28288407 | ||
| Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors | Q28294240 | ||
| Identification of an amplified, highly expressed gene in a human glioma | Q28300727 | ||
| Conservation of the hedgehog/patched signaling pathway from flies to mice: induction of a mouse patched gene by Hedgehog | Q29615369 | ||
| Sonic hedgehog mediates the polarizing activity of the ZPA | Q29616565 | ||
| Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 | Q29617043 | ||
| Prediction of central nervous system embryonal tumour outcome based on gene expression | Q29618619 | ||
| Epigenetics and cancer without genomic instability. | Q33346513 | ||
| Gli genes and limb development | Q33592073 | ||
| Genetic ablation of Cyclin D1 abrogates genesis of rhabdoid tumors resulting from Ini1 loss | Q33922936 | ||
| Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation. | Q34202062 | ||
| The Gli code: an information nexus regulating cell fate, stemness and cancer. | Q34685494 | ||
| The SWI/SNF complex--chromatin and cancer. | Q35667471 | ||
| Gli1 is a target of Sonic hedgehog that induces ventral neural tube development | Q36870138 | ||
| Small-molecule inhibitors reveal multiple strategies for Hedgehog pathway blockade | Q37291730 | ||
| Hedgehog signaling in development and cancer. | Q37350250 | ||
| Oncogenesis caused by loss of the SNF5 tumor suppressor is dependent on activity of BRG1, the ATPase of the SWI/SNF chromatin remodeling complex. | Q37389731 | ||
| Hijacking the chromatin remodeling machinery: impact of SWI/SNF perturbations in cancer | Q37618471 | ||
| Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist | Q39151730 | ||
| Loss of the epigenetic tumor suppressor SNF5 leads to cancer without genomic instability. | Q39949572 | ||
| Loss of the hSNF5 gene concomitantly inactivates p21CIP/WAF1 and p16INK4a activity associated with replicative senescence in A204 rhabdoid tumor cells | Q40351489 | ||
| Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449 | Q42031842 | ||
| Understanding the words of chromatin regulation | Q42274324 | ||
| Sporadic medulloblastomas contain PTCH mutations. | Q42434884 | ||
| The c-myc gene is a direct target of mammalian SWI/SNF-related complexes during differentiation-associated cell cycle arrest | Q42805596 | ||
| Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. | Q44086955 | ||
| Chromatin immunoprecipitation assay for mammalian tissues | Q44920785 | ||
| Identification of a prx1 limb enhancer. | Q52169507 | ||
| Expression of Cre recombinase in the developing mouse limb bud driven by aPrxl enhancer | Q64965676 | ||
| Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5 | Q78570048 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1429-1433 | |
| P577 | publication date | 2010-11-14 | |
| P1433 | published in | Nature Medicine | Q1633234 |
| P1476 | title | Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway | |
| P478 | volume | 16 |
| Q48278066 | A New Way Forward in Cancer Drug Discovery: Inhibiting the SWI/SNF Chromatin Remodelling Complex |
| Q42350797 | A novel independence test for somatic alterations in cancer shows that biology drives mutual exclusivity but chance explains most co-occurrence |
| Q91725342 | A proteomic approach identifies SAFB-like transcription modulator (SLTM) as a bidirectional regulator of GLI family zinc finger transcription factors |
| Q38220523 | A rationale to target the SWI/SNF complex for cancer therapy |
| Q42102894 | Activation of β-catenin/TCF targets following loss of the tumor suppressor SNF5. |
| Q36547802 | Active IKKβ promotes the stability of GLI1 oncogene in diffuse large B-cell lymphoma. |
| Q52878923 | Altered primary chromatin structures and their implications in cancer development. |
| Q35950995 | Anteroposterior Limb Skeletal Patterning Requires the Bifunctional Action of SWI/SNF Chromatin Remodeling Complex in Hedgehog Pathway |
| Q53073070 | Arsenic trioxide inhibits tumor cell growth in malignant rhabdoid tumors in vitro and in vivo by targeting overexpressed Gli1. |
| Q36893203 | Atypical teratoid/rhabdoid tumors-current concepts, advances in biology, and potential future therapies |
| Q41183040 | BRD9 Inhibition, Alone or in Combination with Cytostatic Compounds as a Therapeutic Approach in Rhabdoid Tumors |
| Q92641658 | CDK7 inhibition suppresses aberrant hedgehog pathway and overcomes resistance to smoothened antagonists |
| Q99594988 | COMPASS and SWI/SNF complexes in development and disease |
| Q55177661 | Cancer epigenetics: Moving forward. |
| Q34287662 | Cancer genetics and epigenetics: two sides of the same coin? |
| Q92446415 | Case-based review: atypical teratoid/rhabdoid tumor |
| Q33907067 | Chromatin-regulating proteins as targets for cancer therapy |
| Q47098738 | Combined BRD4 and CDK9 inhibition as a new therapeutic approach in malignant rhabdoid tumors |
| Q89899078 | Concurrent Control of KSHV Life Cycle through Chromatin Modulation and Host Hedgehog Signaling: A New Prospect to the Therapeutic Potential of Lipoxin A4 |
| Q55409347 | Concurrent IDH1 and SMARCB1 Mutations in Pediatric Medulloblastoma: A Case Report. |
| Q27027214 | Context-dependent signal integration by the GLI code: the oncogenic load, pathways, modifiers and implications for cancer therapy |
| Q36658489 | Contextualizing the Genes Altered in Bladder Neoplasms in Pediatric andTeen Patients Allows Identifying Two Main Classes of Biological ProcessesInvolved and New Potential Therapeutic Targets |
| Q82769625 | Crippling SWI-SNF makes tumors GLI-ful |
| Q38011541 | Crosstalk between TGF-β and hedgehog signaling in cancer. |
| Q40172063 | Diagnostic value of next-generation sequencing in an unusual sphenoid tumor. |
| Q37970954 | Diverse functions of ATP-dependent chromatin remodeling complexes in development and cancer |
| Q38639828 | Driver mutations of cancer epigenomes. |
| Q35149722 | Dual role of Brg chromatin remodeling factor in Sonic hedgehog signaling during neural development |
| Q36835530 | Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. |
| Q38058972 | Epigenetic alterations involved in cancer stem cell reprogramming |
| Q42024622 | Epigenetic inactivation of the tumor suppressor BIN1 drives proliferation of SNF5-deficient tumors. |
| Q39069889 | Epigenetic modification in chromatin machinery and its deregulation in pediatric brain tumors: Insight into epigenetic therapies |
| Q34426872 | Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition |
| Q39441283 | Epigenetics and Cancer Stem Cells: Unleashing, Hijacking, and Restricting Cellular Plasticity. |
| Q38709544 | Epigenomic regulation of oncogenesis by chromatin remodeling |
| Q26782730 | Epithelioid Sarcoma: Opportunities for Biology-Driven Targeted Therapy |
| Q35621426 | Epithelioid malignant peripheral nerve sheath tumor arising in a schwannoma, in a patient with "neuroblastoma-like" schwannomatosis and a novel germline SMARCB1 mutation |
| Q27027021 | Extracranial rhabdoid tumours: what we have learned so far and future directions |
| Q35035462 | Fibroblast growth factor receptors as novel therapeutic targets in SNF5-deleted malignant rhabdoid tumors |
| Q92989376 | GLI transcriptional repression regulates tissue-specific enhancer activity in response to Hedgehog signaling |
| Q48740583 | GLI1 Blockade Potentiates the Antitumor Activity of PI3K Antagonists in Lung Squamous Cell Carcinoma |
| Q39013082 | GLI1, a master regulator of the hallmark of pancreatic cancer |
| Q30671578 | Generation of a mouse model of atypical teratoid/rhabdoid tumor of the central nervous system through combined deletion of Snf5 and p53. |
| Q37392280 | Genome-Wide Profiles of Extra-cranial Malignant Rhabdoid Tumors Reveal Heterogeneity and Dysregulated Developmental Pathways. |
| Q48593235 | Germline SMARCE1 mutations predispose to both spinal and cranial clear cell meningiomas |
| Q64245029 | Gli Proteins: Regulation in Development and Cancer |
| Q34981146 | Gli1/DNA interaction is a druggable target for Hedgehog-dependent tumors. |
| Q99591085 | Hedgehog Signaling and Truncated GLI1 in Cancer |
| Q40575110 | INI1 (SMARCB1)-Deficient Sinonasal Carcinoma: A Clinicopathologic Report of 2 Cases |
| Q48738953 | Identification of genes involved in the biology of atypical teratoid/rhabdoid tumours using Drosophila melanogaster |
| Q39126217 | Loss of IGFBP7 expression and persistent AKT activation contribute to SMARCB1/Snf5-mediated tumorigenesis |
| Q48265018 | Loss of Smarc proteins impairs cerebellar development |
| Q45167839 | Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas |
| Q26781877 | Malignant teratoma in Klippel-Feil syndrome: a case report and review of the literature |
| Q34332647 | Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth. |
| Q39794708 | Menin directly represses Gli1 expression independent of canonical Hedgehog signaling |
| Q36401173 | MicroSCALE screening reveals genetic modifiers of therapeutic response in melanoma |
| Q26829103 | Minireview: Conversing with chromatin: the language of nuclear receptors |
| Q38359284 | Molecular biology of pediatric brain tumors and impact on novel therapies |
| Q36561734 | Molecular characterization of metastatic exon 11 mutant gastrointestinal stromal tumors (GIST) beyond KIT/PDGFRα genotype evaluated by next generation sequencing (NGS) |
| Q42416688 | Molecular pathways: SWI/SNF (BAF) complexes are frequently mutated in cancer--mechanisms and potential therapeutic insights. |
| Q34315290 | Morphogen pathways as molecular targets for the treatment of fibrosis in systemic sclerosis |
| Q42514400 | Mutations in ACTRT1 and its enhancer RNA elements lead to aberrant activation of Hedgehog signaling in inherited and sporadic basal cell carcinomas. |
| Q26783611 | Non-Canonical Hh Signaling in Cancer-Current Understanding and Future Directions |
| Q64992804 | Non-canonical Hedgehog Signaling Pathway in Cancer: Activation of GLI Transcription Factors Beyond Smoothened. |
| Q30441193 | Novel insight into mutational landscape of head and neck squamous cell carcinoma |
| Q46075208 | Oncogenic Functions of Gli1 in Pancreatic Adenocarcinoma Are Supported by Its PRMT1-Mediated Methylation |
| Q33607443 | Oncogenic roles of SMARCB1/INI1 and its deficient tumors |
| Q36125613 | Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome |
| Q57962903 | Reproducibility of academic preclinical translational research: lessons from the development of Hedgehog pathway inhibitors to treat cancer |
| Q38083797 | Rhabdoid tumors: an initial clue to the role of chromatin remodeling in cancer |
| Q38121136 | Rhabdoid tumors: clinical approaches and molecular targets for innovative therapy |
| Q55384318 | Role and inhibition of GLI1 protein in cancer. |
| Q38734099 | SMARCA4/Brg1 coordinates genetic and epigenetic networks underlying Shh-type medulloblastoma development |
| Q91976791 | SMARCB1 Gene Mutation Predisposes to Earlier Development of Glioblastoma: A Case Report of Familial GBM |
| Q47925228 | SNF5 as a prognostic factor in skull base chordoma |
| Q39824572 | SNF5 is Involved in Suppression of Hepatocellular Carcinoma Progression via TGF-Beta 1 Signaling |
| Q34699803 | SNF5 is an essential executor of epigenetic regulation during differentiation. |
| Q34518342 | SNF5/INI1 deficiency redefines chromatin remodeling complex composition during tumor development. |
| Q27009284 | SWI/SNF chromatin-remodeling factors: multiscale analyses and diverse functions |
| Q37886668 | SWI/SNF nucleosome remodellers and cancer. |
| Q36456479 | Studying the role of the immune system on the antitumor activity of a Hedgehog inhibitor against murine osteosarcoma |
| Q48743328 | Syndromes predisposing to pediatric central nervous system tumors: lessons learned and new promises |
| Q35369863 | TCR-dependent transformation of mature memory phenotype T cells in mice |
| Q38467989 | Targeted exploration and analysis of large cross-platform human transcriptomic compendia |
| Q35904534 | Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update |
| Q37232227 | Targeting hedgehog signaling in cancer: research and clinical developments |
| Q37689120 | Targeting signal transduction pathways of cancer stem cells for therapeutic opportunities of metastasis |
| Q60954611 | Targeting the Oncoprotein Smoothened by Small Molecules: Focus on Novel Acylguanidine Derivatives as Potent Smoothened Inhibitors |
| Q52323206 | Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. |
| Q34738018 | The BET bromodomain inhibitor I-BET151 acts downstream of smoothened protein to abrogate the growth of hedgehog protein-driven cancers. |
| Q36240079 | The Hedgehog pathway: role in cell differentiation, polarity and proliferation |
| Q38896059 | The Many Roles of BAF (mSWI/SNF) and PBAF Complexes in Cancer |
| Q24338138 | The SWI/SNF Subunit INI1 Contains an N-Terminal Winged Helix DNA Binding Domain that Is a Target for Mutations in Schwannomatosis |
| Q92025302 | The SWI/SNF complex in cancer - biology, biomarkers and therapy |
| Q38826541 | The developmental and pathogenic roles of BAF57, a special subunit of the BAF chromatin-remodeling complex |
| Q34771550 | The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells |
| Q34306294 | The limitations of simple gene set enrichment analysis assuming gene independence |
| Q37601480 | The molecular pathogenesis of schwannomatosis, a paradigm for the co-involvement of multiple tumour suppressor genes in tumorigenesis |
| Q36536422 | The occurrence of intracranial rhabdoid tumours in mice depends on temporal control of Smarcb1 inactivation |
| Q34649133 | The role of genetics in the establishment and maintenance of the epigenome. |
| Q87131861 | Towards risk-adapted therapy for rhabdoid tumour subgroups |
| Q40009547 | Tumor Suppressor Function of CYLD in Nonmelanoma Skin Cancer |
| Q55251323 | Tumorigenic Cell Reprogramming and Cancer Plasticity: Interplay between Signaling, Microenvironment, and Epigenetics. |
| Q38160739 | Unraveling the therapeutic potential of the Hedgehog pathway in cancer |
| Q53116195 | Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria. |
| Q38053857 | What underlies the diversity of brain tumors? |
| Q36657085 | Whole Exome- and mRNA-Sequencing of an AT/RT Case Reveals Few Somatic Mutations and Several Deregulated Signalling Pathways in the Context of SMARCB1 Deficiency |
| Q58753351 | Widespread Expression of Hedgehog Pathway Components in a Large Panel of Human Tumor Cells and Inhibition of Tumor Growth by GANT61: Implications for Cancer Therapy |
| Q34991075 | Wongabel rhabdovirus accessory protein U3 targets the SWI/SNF chromatin remodeling complex |
Search more.